- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1610964-64-1] Unesbulin
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-112041 |
| Brand: | MCE |
| CAS: | 1610964-64-1 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 420.34 |
| Molecular Formula | C19H13F5N6 |
| SMILES | NC1=C(F)C(NC2=CC=C(C(F)(F)F)C=C2)=NC(N3C4=CC(F)=CC=C4N=C3C)=N1 |
3 Publications Citing Use of MCE
Summary
Unesbulin (PTC596) is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 ( BMI-1 ) inhibitor. Unesbulin downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia (AML) cells. Unesbulin has anti-leukemic activity [1] [2] .
IC50 & Target
BMI-1 [1]
In Vitro
Unesbulin (PTC596; 20-200 nM; for 48 hours) induces apoptosis in AML cells in a p53-independent manner. BMI-1 overexpression desensitizes AML cells to PTC596-induced apoptosis
[1]
.
Unesbulin (200 nM; for 10 hours) leads to an accumulation of cells in G2/M phase
[1]
.
Unesbulin (0.012-1 μM; for 20 hours) significantly reduces protein levels of BMI-1
[1]
.
Unesbulin inhibits APC/CCDC20 activity resulting in the persistent activation of CDK1 and CDK2 which mediate the hyperphosphorylation of BMI1
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Apoptosis Analysis [1]
| Cell Line: | AML cell lines (MOLM-13, OCI-AML3, MOLM-14, MV4-11, U-937, HL-60) |
| Concentration: | 20, 50, 100, 200 nM |
| Incubation Time: | For 48 hours |
| Result: | Induced apoptosis in a dose- and time-dependent manner with the average IC 50 and ED 50 values among six cell lines were 30.7 nM and 60.3 nM, respectively. |
Cell Cycle Analysis [1]
| Cell Line: | MOLM-13 and U-937 cells |
| Concentration: | 200 nM |
| Incubation Time: | For 10 hours |
| Result: | Led to an accumulation of cells in G2/M phase, whereas the percentage of cells in G1 phase decreased. |
Western Blot Analysis [1]
| Cell Line: | MOLM-13 cell |
| Concentration: | 0.012, 0.037, 0.11, 0.33, 1 μM |
| Incubation Time: | For 20 hours |
| Result: |
Significantly reduced protein levels of BMI-1 and its downstream target ubiquitinated histone H2A.
Increased cyclin B1 and securin levels. |
In Vivo
Unesbulin (PTC596; 5 mg/kg; oral gavage; every 3 days for 13 days) significantly prolongs mouse survival
[1]
.
Unesbulin (20 mg/kg; oral gavage; once a week for 15 days) causes tumor volume significantly smaller than that of control SCID mice with K562 cells
[1]
.
Unesbulin (10 or 12.5 mg/kg; oral gavage; twice a week until death) causes the survival significantly longer than the vehicle-treated group in NOD-SCID mice with HL-60 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | NOD-SCID/IL2Rγ-KO (NSG) mice with MOLM-13 cells [1] |
| Dosage: | 5 mg/kg |
| Administration: | Oral gavage; every 3 days for 13 days |
| Result: | Significantly prolonged mouse survival compared with the vehicle-treated mice in a dose-dependent manner. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02404480 | PTC Therapeutics |
Cancer
|
January 2016 | Phase 1 |
| NCT03206645 | University of Oklahoma|PTC Therapeutics |
Ovarian Cancer
|
August 28, 2017 | Phase 1 |
| NCT03605550 | Nationwide Children´s Hospital|PTC Therapeutics |
High Grade Glioma|Diffuse Intrinsic Pontine Glioma
|
August 1, 2018 | Phase 1 |
| NCT05269355 | PTC Therapeutics |
Leiomyosarcoma
|
May 23, 2022 | Phase 2|Phase 3 |
| NCT03761095 | PTC Therapeutics |
Leiomyosarcoma
|
March 13, 2019 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 16.67 mg/mL ( 39.66 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3790 mL | 11.8951 mL | 23.7903 mL |
| 5 mM | 0.4758 mL | 2.3790 mL | 4.7581 mL |
| 10 mM | 0.2379 mL | 1.1895 mL | 2.3790 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 1.67 mg/mL (3.97 mM); Clear solution
References
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.